While whether these effects indeed account for mansaantin A-mediated HIF-1 inhibition remains an interesting question to be answered, the fact that LXY6006 is a more potent HIF-1 inhibitor suggests that LXY6006 could be a useful tool for dissecting the mechanism underlying the anti-cancer activity of manssantin A-derived agents. Here, SETD2 is linked to cancer.